Takeda Grows Immuno-Oncology Portfolio With $525m Maverick Acquisition
Japanese Pharma Exercises Option Under 2017 Deal
Maverick’s bispecific antibody program adds to Takeda’s expanding immuno-oncology development business, which also includes cell therapy programs.
You may also be interested in...
The recently concluded BIO annual meeting included several sessions focused on the practice of business development. In this extra edition of our BIO 2021 notebook, Scrip collected observations about best practices for partnerships.
Cell, gene and RNA therapies are starting to transform the healthcare landscape and a report from the American Society of Gene + Cell Therapy and Informa Pharma Intelligence maps the progress the sector made in the first quarter of 2021.
Plus deals involving I-Mab/Complix, Lupin/Endoceutics, Genome & Co/Pfizer/Merck KGaA, Genome & Co/Debiopharm, Exelixis/WuXi, Intas/Foresee, Wugen/Alpha Biosciences